Clinical Trials
40 trialsCRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Caribou Biosciences, Inc.
A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas
Shanghai Hengrui Pharmaceutical Co., Ltd.
A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma
First Affiliated Hospital of Zhejiang University
ANCHOR2
Athenex, Inc.
Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
ThisCART19A for B-NHL Relapsed After Auto-CAR T
The First Affiliated Hospital of Soochow University
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
Ascentage Pharma Group Inc.
Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies
Sichuan University
Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL
Second Affiliated Hospital, School of Medicine, Zhejiang University
Natural Killer (NK) Cell Therapy for B-Cell Malignancies
Zhejiang University
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)
Shanghai Miracogen Inc.
Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
Second Affiliated Hospital, School of Medicine, Zhejiang University
Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia
Yan'an Affiliated Hospital of Kunming Medical University
Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors
Xuzhou Medical University
Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma
Shenzhen BinDeBio Ltd.
Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma
UWELL Biopharma
CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
Shanghai Tong Ren Hospital
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma
Oncotartis, Inc.
Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell Lymphoma
First Affiliated Hospital of Zhejiang University
A-319
EVIVE Biotechnology
Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
Wuhan Sian Medical Technology Co., Ltd
CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.
Xijing Hospital
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma
Henan Cancer Hospital
Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies
Henan Cancer Hospital
CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia
Yan'an Affiliated Hospital of Kunming Medical University
Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma
Peking University
A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT
Shenzhen Second People's Hospital
The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma
Shanghai Longyao Biotechnology Inc., Ltd.
A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia
Immune Cell, Inc.
A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL
Shanghai AbelZeta Ltd.
Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
Pinze Lifetechnology Co. Ltd.
Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma
Peking University
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
Henan Cancer Hospital